Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aneurysm & intracranial embolization cases in Oregon: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 63 | 50% |
| 2020 | 0 | 31 | 51% |
| 2021 | 0 | 46 | 53% |
| 2022 | 1 | 62 | 56% |
| 2023 | 0 | 67 | 58% |
| 2024 | 2 | 108 | 59% |
| 2025 from claims | – | 95 77–112 | 59% |
| 2026 forecast | – | 106 83–133 | 58% |
| 2027 forecast | – | 116 86–153 | 58% |
| 2028 forecast | – | 127 90–175 | 58% |
| 2029 forecast | – | 139 94–199 | 58% |
| 2030 forecast | – | 152 99–225 | 58% |
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Oregon; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 48 | 1,774+17%/yr | +17%/yr | 0.5 | 0% | 3,530 in 2030+12%/yr |
| Washington | 12 | 398+16%/yr | +16%/yr | 0.5 | 0% | 840 in 2030+13%/yr |
| Arizona | 12 | 342+14%/yr | +14%/yr | 0.5 | 0% | 770 in 2030+14%/yr |
| Colorado | 6 | 214+15%/yr | +15%/yr | 0.4 | 0% | 430 in 2030+12%/yr |
| Nevada | 3 | 177+15%/yr | +15%/yr | 0.6 | 0% | 310 in 2030+9.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 1 | 130−4.5%/yr | −4.5%/yr | 0.30.8× | 0% | 270 in 2030+13%/yr |
| DBS & VNS | 2 | 124−13%/yr | −13%/yr | 0.30.9× | 0% | 140 in 2030+1.9%/yr |
Aneurysm & intracranial embolization in every state, and its device makers · Every procedure market in Oregon · Every state · Compare with California
Microvention leads with 76% of company spending on these surgeons in 2025, +29 pts on 2024.
In 2025, 7 companies reported engagement with Oregon’s surgeons worth $52K in consulting, speaking, meals and travel tied to these products, about $26K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.